Shots:

• The study involves assessing  multistem therapy (IV)(n=20) vs PBO (n=10) in patients with ARDS for 28 days
• Study results: Lower mortality (LM)(25% vs 40%); VF days (12.9 vs 9.2); ICU-free days (10.3 vs 8.1); In severe ARDS: LM (25% vs 50%); ventilator-free (VF)@ days (14.6 vs 8.0); ICU-free @days (11.4 vs 5.9) and was well tolerated
• Multistem Cell Therapy (IV) is a regenerative product- targeted for tissue repairing including healing for multiple therapeutic areas. Athersys is also conducting P-III MASTER-2 study for patients with ischemic stroke and acute MI

 Ref: Globe Newswire  | Image: Youtube